Chronic lymphocytic leukemia : diagnosis, treatment options and prognosis / Kimberly Rodriguez, editor.

Format:

Book

Contributor:

Rodriguez, Kimberly, editor.

Series:

Cancer etiology, diagnosis, and treatments.

Cancer Etiology, Diagnosis and Treatments

Language:

English

Subjects (All):

Chronic lymphocytic leukemia.

Physical Description:

1 online resource (173 p.)

Place of Publication:

New York : Nova Biomedical, 2016.

Summary:

Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in the western world, seen mostly in the elderly age-group and has a very variable clinical outcome. Traditionally considered an indolent, antigen inexperienced leukemia of slowly accumulating cells that do not die, researchers now acknowledge that CLL cells are highly proliferative, antigen experienced cells that have a high cell turnover and a subset show an aggressive clinical course. The onset of the disease is usually asymptomatic; only abnormalities in whole blood count such as leukocytosis with lymphocytosis are found. Nowadays, CLL is diagnosed more often at an early, asymptomatic stage due to more frequent routine blood tests. More advanced stages are characterized by lymphadenopathy, hepatomegaly/splenomegaly, recurrent infections, weakness, pallor and hemorrhagic diathesis, and general symptoms such as weight loss, fever and night sweats are observed. This book reviews the diagnosis, treatment options and prognosis of CLL.

Contents:

CHRONIC LYMPHOCYTIC LEUKEMIA: DIAGNOSIS, TREATMENT OPTIONS AND PROGNOSIS; CHRONIC LYMPHOCYTIC LEUKEMIA: DIAGNOSIS, TREATMENT OPTIONS AND PROGNOSIS; Library of Congress Cataloging-in-Publication Data; CONTENTS; PREFACE; Chapter 1: THE CHEMOKINE RECEPTOR CCR3 IN CHRONIC LYMPHOCITIC LEUKEMIA: POSSIBLE BIOLOGICAL ROLE IN THE COURSE OF THE DISEASE; ABSTRACT; INTRODUCTION; MATERIALS AND METHODS; Patients; Flow Cytometry; Statistical Analysis; RESULTS; DISCUSSION; CONCLUSION; REFERENCES; BIOGRAPHICAL SKETCH; Chapter 2: NEW AND REPOSITIONING APPROACHES TO THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

ABSTRACT1. INTRODUCTION; 2. NEW TARGETED THERAPIES FOR CLL; 2.1. B-Cell Receptor (BCR) Inhibitors; 2.1.1. BTK Inhibition; 2.1.1.1. Ibrutinib; 2.1.1.2. Spebrutinib; 2.1.1.3. Acalbrutinib; 2.1.1.4. ONO-4059; 2.1.2. PI3 Kinase Inhibition; 2.1.2.1. Idelalisib; 2.1.2.2. Duvelisib; 2.1.2.3. TGR-1202; 2.1.3. Pan-PI3K/mTOR Inhibition; 2.1.4. SYK Inhibition; 2.1.4.1. Fostamatinib; 2.1.4.2. Entospletinib; 2.1.5. LYN Inhibition; 2.1.5.1. Dasatynib; 2.2. BCL2 Inhibitors; 2.2.1. Venetoclax; 2.2.2. Navitoclax; 2.2.3. Obatoclax; 2.3. NF-kB Targeting Agents; 3. REPOSITIONING DRUGS TO CLL TREATMENT

3.1. Metformin3.2. Statins; 3.3. Danazol; 3.4. Valproic Acid; 4. NANOPARTICLE BASED THERAPEUTICS APPROACH TO CLL TREATMENT; 4.1. Dendrimers; CONCLUSION; REFERENCES; BIOGRAPHICAL SKETCHES; Chapter 3: PROGNOSTIC AND PREDICTIVE INDICATORS IN CHRONIC LYMPHOCYTIC LEUKEMIA; ABSTRACT; HISTORICAL PERSPECTIVE; TRADITIONAL STAGING SYSTEMS; CYTOGENETIC ABNORMALITIES; STIMULATED CLL KARYOTYPING; IGHV MUTATION STATUS; SERUM MARKERS; CELL SURFACE MARKERS; SOMATIC MUTATIONS; MICRORNA'S; CLOSING REMARKS: USING BIOMARKERS ON THE ROAD TO CURE; REFERENCES

Chapter 4: MOLECULAR CYTOGENETIC ABNORMALITIES IN CHRONIC LYMPHOCYTIC LEUKEMIA: PROGNOSTIC IMPLICATIONSABSTRACT; INTRODUCTION; CHROMOSOMAL ABERRATIONS IN CLL; B Cell Receptors (BCRs); Novel Mutations in CLL; Clonal Evolution and the Driver/Passenger Mutation Modelin CLL; Hierarchal Classification; MicroRNAs; CONCLUSION; ACKNOWLEDGMENTS; REFERENCES; INDEX; Blank Page

Notes:

Description based upon print version of record.

Includes bibliographical references at the end of each chapters and index.

Description based on print version record.

ISBN:

1-63485-547-7